Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D

Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D

Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D. According to a Hindustan Times story, the Covid-19 vaccine ZyCov-D may be introduced by the Ahmedabad-based pharmaceutical company Zydus Cadila into the national vaccination scheme the next week.

The Union Government has chosen to use ZyCov-D, a DNA-based and needle-free Covid-19 vaccine, first on adults, according to the report. It has been approved for emergency use for those 12 years of age and older. In the first phase in seven states. Bihar, Jharkhand, Maharashtra, Punjab, Tamil Nadu, Uttar Pradesh, and West Bengal are the seven states.

A painless vaccination experience is provided with a needle-free vaccine, which also lessens serious adverse effects. ‘PharmaJet’, a painless needle-free application, will be used to provide the vaccination.

Each dosage of the vaccination costs 358 dollars, which is made up of 265 dollars for each shot and an additional 93 dollars for the needle-free applicator. The prices do not include GST. ZyCov-D must be taken in three doses separated 28 days apart. The Drug Controller General of India (DGCI) already approved the ZyCov-D vaccine for emergency use in August 2021. The Indian government had already requested one crore dose of ZyCov-D.


World’s First DNA-Based Vaccine

The ZyCoV-D is the first DNA-based COVID-19 vaccine to be delivered to humans, including children and adults 12 years and older, and it was developed entirely by India.  The vaccine has been developed in partnership with the Department of Biotechnology (DBT), under the ‘Mission COVID Suraksha’, implemented by BIRAC, a PSU of DBT. Currently, no DNA vaccines have been approved for use in humans. But many DNA vaccines are undergoing human clinical trials and some DNA vaccines have been approved by US regulatory agencies.

Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D

Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D

The painless PharmaJet® needle-free device, Tropis®, is used to administer the three doses of ZyCoV-D intradermally on days 0, 28, and 56. According to the organisation, over 50 centres in India have participated in the vaccine’s largest clinical trial to date. The cost of the vaccine, excluding GST, will be Rs 265 per dosage, while the cost of the applicator will be Rs 93 per dose.

ZyCoV-D is a Plasmid DNA vaccine that, when given, causes the SARS-CoV-2 virus’ spike protein to be produced. This immune response is mediated by the cellular and humoral arms of the human immune system, which are crucial for both disease protection and viral clearance.

The Ahmedabad-based pharma solid says that the plasmid DNA platform’s plug-and-play technology can be simply modified to deal with virus modifications, such as those that are now taking place. A quick lesson will be delivered to frontline staff and vaccine administrators on how to use the needle-free pharma jet management in practical field situations for the adult population.

The company obtained a 1 crore vaccination order from the centre in November of last year, paying Rs 358 for each dose.  The three vaccinations now used in India—Covishield, Covaxin, and Sputnik V—are joined by ZyCoV-D. Currently, the only vaccine being administered in children is Covaxin while two more shots (Covovax and Corbevax) are in the pipeline after receiving the Drug Controller General of India’s clearance for Emergency use in 2021.

How Are Needle-Free Injections Administered

A tiny stream of fluid is used by needle-free injectors to get under the skin and deliver the vaccine to the desired level in the tissue. The company claims that this technology can drastically lessen any possible adverse effects while also reducing the possibility of needlestick injuries. Patients with trypanophobia, a condition typified by a base fear of blood or needles, would also benefit from it.



On July 1st, 2021, Cadila Healthcare submitted an application to the Drugs Controller General of India (DCGI). Therefore, it asked for authorization to exclusively use the vaccine in select, critical circumstances. The DCGI should grant the request on August 20, 2021, according to the advice of the CDSCO Subject Expert Committee.

Also Read: What Product Owner Certification Is and Some of the Best Ones In 2022


ZyCoV-D is India’s first DNA Vaccine for the COVID-19 virus. “Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D” reported on it and talked about how revolutionary it is. So we talked about what ZyCoV-D is, its chemical description in simple terms, and how the vaccine is administered. Additionally, we also talked about the authorizations it received and its deployment. The take of “Rajkotupdates.news : Zydus Needle Free Corona Caccine Zycov D” on ZyCoV-D was expanded in this blog.


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.